Codexis, Inc. (CDXS) News
Filter CDXS News Items
CDXS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CDXS News Highlights
- CDXS's 30 day story count now stands at 3.
- Over the past 16 days, the trend for CDXS's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- RNA are the most mentioned tickers in articles about CDXS.
Latest CDXS News From Around the Web
Below are the latest news stories about CODEXIS INC that investors may wish to consider to help them evaluate CDXS as an investment opportunity.
Codexis to Participate in Jefferies Healthcare ConferenceREDWOOD CITY, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will attend the Jefferies Healthcare Conference, being held June 7-9, 2023, in New York, New York. Management will participate in a fireside chat on Wednesday, June 7, 2023, at 1:00 pm ET. A live webcast of the event will be available in the Investor Relations section of the Company’s website, http://ir.codexis.com. A replay will be archived for 9 |
Codexis Unveils ECO Synthesis™ Platform for Large-Scale RNAi Therapeutics Production at TIDES USA--Proprietary technology being developed to address sustainability and scalability challenges of oligonucleotide manufacturing--REDWOOD CITY, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the unveiling of its Enzyme-Catalyzed Oligonucleotide (ECO) Synthesis™ technology, a proprietary new synthesis platform being developed for manufacturing RNA oligonucleotide therapeutics at scale. The ECO Synthesis™ technology was un |
Codexis Announces New Employment Inducement GrantsREDWOOD CITY, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the approval of equity grants to five new employees as approved by the Compensation Committee of Codexis’s Board of Directors. The newly hired employees received equity awards consisting of an aggregate of (i) options to purchase 56,773 shares of Codexis common stock and (ii) restricted stock units (RSUs) for 35,037 shares of Codexis common stock as inducemen |
Codexis (CDXS) Reports Q1 Loss, Lags Revenue EstimatesCodexis (CDXS) delivered earnings and revenue surprises of -17.24% and 11.34%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock? |
Codexis Reports First Quarter 2023 Financial ResultsCDX-7108 Clinical Development Program Remains on Track Estimated Cash Runway Through End of 2024 Funds Important Upcoming Milestones Company Reiterates 2023 Total Revenue Guidance with Adjustments to Product vs. R&D Revenue Mix and Range on Gross Margin REDWOOD CITY, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced financial results for the first quarter ended March 31, 2023, and provided a business update. “We had a pro |
Will Alimera Sciences (ALIM) Report Negative Q1 Earnings? What You Should KnowAlimera Sciences (ALIM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
What Is Codexis, Inc.'s (NASDAQ:CDXS) Share Price Doing?Codexis, Inc. ( NASDAQ:CDXS ), is not the largest company out there, but it received a lot of attention from a... |
Codexis (CDXS) Expected to Beat Earnings Estimates: Should You Buy?Codexis (CDXS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
Codexis to Report First Quarter 2023 Financial Results on May 4REDWOOD CITY, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the first quarter of 2023 on Thursday, May 4, 2023, following the close of market. The Company will not be conducting a conference call in conjunction with this financial results release. About Codexis Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver® technology platform to |
Codexis Announces RNA Therapeutics Manufacturing Workshop at TIDES USAREDWOOD CITY, Calif., April 19, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it will host a pre-conference workshop highlighting the role of an enzymatic approach to support RNA-based therapeutics manufacturing at the TIDES USA annual meeting being held May 7-10, 2023, in San Diego, CA. The workshop will be held live and virtually on Sunday, May 7, 2023. Ribonucleic acid (RNA) as a therapeutic modality has gained tremendous traction |